Last reviewed · How we verify
NCT06972212
Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults
EARLY_PHASE1 trial testing suzetrigine 100mg in Pain Detection in 20 participants. Completed in 28 June 2025.
28 June 2025
Quick facts
| Lead sponsor | Latigo Biotherapeutics |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 4 June 2025 |
| Primary completion | 28 June 2025 |
| Estimated completion | 28 June 2025 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- suzetrigine 100mg — full drug profile →
- Placebo
Conditions studied
- Pain Detection — all drugs for Pain Detection →
- Pain Threshold — all drugs for Pain Threshold →
Sponsor
Latigo Biotherapeutics — full company profile →
Who can join
Adults 18 to 55, male only, with Pain Detection or Pain Threshold. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test. The study will be conducted at a single center in New Zealand.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Suzetrigine, a Non-Opioid Small-Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science.
Rajasingham R, Qi Y. · · 2025 · cited 3× · PMID 41251403 · DOI 10.1111/cts.70414 -
Suzetrigine, a Na<sub>V</sub>1.8 Inhibitor as a Novel Approach for Pain Therapy-A Medicinal and Chemical Drug Profile.
Medhat RM, Kotb OA, Baecker D. · · 2026 · cited 1× · PMID 41599406 · DOI 10.3390/molecules31020358
Verify or expand the search:
- PubMed search for NCT06972212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Latigo Biotherapeutics trials
Trials by the same sponsor.
- NCT07341152 — A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants · Phase 1 · completed
- NCT07102459 — An Efficacy and Safety Study of LTG-001 Following Abdominoplasty · Phase 2 · completed
- NCT06774625 — This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Mo · Phase 2 · completed
- NCT06600607 — Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults · EARLY_PHASE1 · completed
- NCT06554574 — A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06972212 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Latigo Biotherapeutics
- Last refreshed: 3 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06972212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing